使用Papillon+系统进行乳腺癌术中放射治疗的可行性与早期毒性:首批结果
这项II期研究评估Papillon+系统用于乳腺癌术中放射治疗的可行性与早期毒性,纳入26例年龄≥60岁、单灶导管性乳腺腺癌≤2.5 cm、分级1-2级的患者,处方剂量20 Gy。主要终点为Gafchromic胶片测量的剂量,中位随访12个月,未观察到>2级皮肤或皮下毒性、无局部复发和转移。
要点
- 纳入26例年龄≥60岁、单灶导管性乳腺腺癌≤2.5 cm、分级1-2级患者,处方剂量20 Gy。
- Gafchromic胶片平均剂量:南极18.8 Gy±2 Gy、赤道15.6 Gy±2.81 Gy、皮肤2.5 Gy±1.67 Gy。
- 中位随访12个月,无>2级皮肤或皮下毒性、无局部复发和转移。
核心结论
- 这是首个测试Papillon+系统用于乳腺癌术中放射治疗并进行活体剂量测定的II期研究,临床数据令人安心。
研究设计与样本
- 这是一项在尼斯开展的II期研究,纳入26例年龄≥60岁、单灶导管性乳腺腺癌≤2.5 cm、分级1-2级的患者,行手术局部切除加前哨淋巴结清扫,切除后将施源器置于瘤床,处方剂量20 Gy。
- 主要终点为Gafchromic胶片测量的剂量,两张胶片位于皮肤表面,两张位于切除腔;次要终点为早期毒性和无复发生存。
主要发现
- 2018年10月至2019年9月共纳入26例患者。
- Gafchromic胶片平均剂量为南极18.8 Gy±2 Gy、赤道15.6 Gy±2.81 Gy、皮肤2.5 Gy±1.67 Gy。
- 中位随访12个月,未观察到>2级皮肤或皮下毒性,无局部复发和转移。
关键数值与推荐
- 处方剂量为20 Gy。
- Papillon+TM接触X射线机设计产生50 kVp束,高剂量率≥15 Gy/分钟。
- Gafchromic胶片平均剂量:南极18.8 Gy±2 Gy、赤道15.6 Gy±2.81 Gy、皮肤2.5 Gy±1.67 Gy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Breast intra operative radiation therapy has been evaluated with different systems delivering 20-21 Gy with treatment times around 30 min. Papillon + TM Contact X-ray machine was designed to produce a 50 kVp beam with a high dose rate ≥ 15 Gy/minute. A pilot study with the first prototype was conducted in Nice. MATERIALS AND METHODS: The inclusion criteria were age ≥ 60 years, unifocal ductal breast adenocarcinoma ≤ 2.5 cm, grade 1-2. Surgical local excision with sentinel node dissection was performed and the applicator was placed in the tumor bed after excision with a prescribed dose of 20 Gy. The main end point of the study was the doses measured with the Gafchromic films; two were located at the skin surface and two in the excision cavity. Secondary endpoints were early toxicity and relapse free survival. RESULTS: Between 10/2018 and 09/2019, 26 patients were included. Mean Gafchromic doses were 18.8 Gy ± 2 Gy at the south pole, 15.6 Gy ± 2.81 Gy at the equator and 2.5 Gy ± 1.67 Gy at the skin. With a median follow-up time of 12 months, no skin or subcutaneous toxicity > grade 2, no local relapse and no metastasis were observed. CONCLUSION: This is the first phase II study testing the Papillon + tm system for breast IORT with in vivo dosimetry measurements and reassuring clinical data.
引用
- Chand-Fouché ME, Colnard C, Gal J, et al. Feasibility and early toxicity of intraoperative radiotherapy for breast cancer using the papillon + system: First results. Clin Transl Radiat Oncol. 2022. PMID: 36353651. doi:10.1016/j.ctro.2022.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。